NCT00242710View on ClinicalTrials.gov

Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women

PHASE3CompletedINTERVENTIONAL
Enrollment

1,083

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions
Endometrial HyperplasiaOsteoporosis
Interventions
DRUG

Bazedoxifene/Conjugated Estrogen

Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.

DRUG

Bazedoxifene/Conjugated Estrogen

Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.

DRUG

CE 0.45 mg/MPA 1.5mg

Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.

OTHER

Placebo

Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.

Trial Locations (9)

15206

Pfizer Investigational Site, Pittsburgh

30033

Pfizer Investigational Site, Decatur

33409

Pfizer Investigational Site, West Palm Beach

34452

Pfizer Investigational Site, Inverness

59102

Pfizer Investigational Site, Billings

91786

Pfizer Investigational Site, Upland

96814

Pfizer Investigational Site, Honolulu

97401

Pfizer Investigational Site, Eugene

40536-0293

Pfizer Investigational Site, Lexington

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00242710 - Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women | Biotech Hunter | Biotech Hunter